Articles from Orthofix Medical Inc.

Orthofix Medical Inc. (NASDAQOFIX), a leading global medical technology company, today announced that it will release its fourth quarter and full-year 2024 financial results on Tuesday, February 25, 2025 before market open. The Company will host a conference call and webcast to review results at 8:30 am Eastern Time the same day.

Orthofix Medical Inc. (NASDAQOFIX), a leading global medical technology company, today announced that Massimo Calafiore, President and Chief Executive Officer, and Julie Andrews, Chief Financial Officer, will participate in the following investor conferences:

Orthofix Medical Inc. (NASDAQOFIX), a leading global medical technology company, today announced the entry into a new credit agreement providing the Company with up to $275 million in a senior-secured term loan with a 48-month interest only period. The term loan is agented by Oxford Finance LLC (“Oxford”) and provides non-dilutive capital and financial flexibility to support Orthofix’s continued focus on profitable growth. The proceeds from the initial funding of the term loan will be used to retire the Company’s existing credit facility and pay related fees and expenses. The remaining capacity will bolster the Company’s access to capital.

Orthofix Medical Inc. (NASDAQOFIX), a leading global medical technology company, today reported its financial results for the third quarter ended September 30, 2024, reiterated its full-year 2024 financial guidance, and introduced new three-year financial targets.

Orthofix Medical Inc. (NASDAQOFIX), a leading global medical technology company, today announced that the Company will participate in the Stifel 2024 Healthcare Conference in New York. Management is scheduled to present on Monday, November 18, 2024 at 8:35 am ET.

Orthofix Medical Inc. (NASDAQOFIX), a leading global medical technology company, today announced that it will release its third quarter 2024 financial results on Thursday, November 7, 2024 before market open. The Company will host a conference call and webcast to review results at 8:30 am ET the same day.

Orthofix Medical Inc. (NASDAQOFIX), a leading global medical technology company, today announced the presentation of new data supporting the use of Orthofix’s proprietary Pulsed Electromagnetic Field (PEMF) stimulation to increase fusion rates as an adjunct to lumbar spine fusion surgery. Patients treated with the SpinalStim™ bone growth therapy device demonstrated a high rate of successful fusion with significant improvements in pain, function and quality of life, despite having risk factors for pseudarthrosis.

Orthofix Medical Inc. (NASDAQOFIX), a leading global spine and orthopedics company, today announced the appointment of Patrick Fisher as President of the Orthofix Global Orthopedics business. In this role, Fisher will serve on the company’s Executive Leadership team, reporting to Orthofix President and CEO Massimo Calafiore.

Orthofix Medical Inc. (NASDAQOFIX) today reported its financial results for the second quarter ended June 30, 2024 and increased its full-year 2024 financial guidance.

Orthofix Medical Inc. (NASDAQOFIX), a leading global spine and orthopedics company, today announced that the Company will participate in Canaccord Genuity's 44th Annual Growth Conference in Boston. Management is scheduled to present on Wednesday, August 14, 2024 at 2:30 pm ET.

Orthofix Medical Inc. (NASDAQOFIX), a leading global spine and orthopedics company, today announced the appointment of Stephanie Walsh as Chief Human Resources Officer.

Orthofix Medical Inc. (NASDAQOFIX), a leading global spine and orthopedics company, today announced that it will release its second quarter 2024 financial results on Tuesday, August 6, 2024 before market open. The Company will host a conference call and webcast to review results at 8:30 am ET the same day.

Orthofix Medical Inc. (NASDAQOFIX), a leading global spine and orthopedics company, today announced the 510(k) clearance and first U.S. implant of the Fitbone™ Transport and Lengthening System. Used to treat large bone defects in the femur and tibia due to trauma, infectious or malignant conditions, the device is the only intramedullary nail designed to transport or lengthen the bone through a single surgery.

Orthofix Medical Inc. (NASDAQOFIX), a leading global spine and orthopedics company, today announced the appointment of Michael Finegan as Chair of the Board of Directors.

Orthofix Medical Inc. (NASDAQOFIX), a leading global spine and orthopedics company, today announced the appointment of Aviva McPherron as President of Global Operations and Quality. As a member of the Executive Leadership Team, McPherron will oversee strategy for the company’s operations, manufacturing, regulatory, clinical, and quality teams.

Orthofix Medical Inc. (NASDAQOFIX), a leading global spine and orthopedics company, today announced the appointment of Julie Dewey as Chief Investor Relations and Communications Officer. Additionally, as previously announced, Max Reinhardt begins as President of the company’s global spine business. Dewey and Reinhardt will serve on Orthofix’s Executive Leadership Team.

Orthofix Medical Inc. (NASDAQOFIX), a leading global spine and orthopedics company, today announced the appointment of Max Reinhardt as President of the Global Spine business effective June 10, 2024. Reinhardt will serve on the Executive Leadership Team and be responsible for leading SeaSpine, the Company’s global spine and biologics business.

Orthofix Medical Inc. (NASDAQOFIX), a leading global spine and orthopedics company, today announced that it has been selected as winner of the “Best Patient Experience Solution” award in the 8th annual MedTech Breakthrough Awards program. MedTech Breakthrough is an independent market intelligence organization that recognizes the top companies, technologies and products in the global digital health and medical technology market.

Orthofix Medical Inc. (NASDAQOFIX), a leading global spine and orthopedics company, today announced that it has received U.S. Food and Drug Administration (FDA) 510(k) clearance to market its Rodeo™ Telescopic Nail.

Orthofix Medical Inc. (NASDAQOFIX) today reported its financial results for the first quarter ended March 31, 2024.

Orthofix Medical Inc. (NASDAQOFIX), a leading global spine and orthopedics company, today announced that it will release its first quarter 2024 financial results on Tuesday, May 7, 2024 before market open. The Company will host a conference call and webcast to review results at 8:30 a.m. ET the same day.

Orthofix Medical Inc. (NASDAQOFIX), a leading global spine and orthopedics company, today announced that Andres Cedron has joined the company as Chief Legal Officer.

Orthofix Medical Inc. (NASDAQOFIX), a leading global spine and orthopedics company, today announced that Lucas Vitale has joined the company in the newly created role of Chief People and Business Operations Officer.

Orthofix Medical Inc. (NASDAQOFIX) today reported its financial results for the fourth quarter and year ended December 31, 2023, and issued guidance for the full year 2024.

Orthofix Medical Inc. (NASDAQOFIX), a leading global spine and orthopedics company, today announced the appointment of Jason Shallenberger to President of the Bone Growth Therapies business, and the realignment of its Spine business unit, effective March 1. A seasoned sales leader, Shallenberger previously served as Vice President of U.S. Sales and Marketing for the Orthofix Bone Growth Therapies business.

Orthofix Medical Inc. (NASDAQOFIX), a leading global spine and orthopedics company, today announced that it will release its fourth quarter and full year 2023 financial results on Tuesday, March 5, 2024 after market close. The Company will host a conference call and webcast to review results at 4:30 p.m. ET the same day.

Orthofix Medical Inc. (NASDAQOFIX), a leading global spine and orthopedics company, today announced it has entered into an agreement with MRIguidance to distribute its BoneMRI™ imaging software in the U.S. The Company also announced the successful completion of the world’s first eight cases utilizing BoneMRI software with 7D’s FLASH™ Navigation System. BoneMRI creates a synthetic CT from an MRI imaging exam without the use of harmful radiation. For the first time, surgeons, their staff, and patients can now benefit from completely radiation-free preoperative imaging and spinal navigation using BoneMRI with the 7D FLASH Navigation System.

Orthofix Medical Inc. (NASDAQOFIX), a leading global spine and orthopedics company, today announced that Julie Andrews has officially stepped into the role of Chief Financial Officer (CFO). A seasoned executive, Ms. Andrews previously served as CFO for Smart Wires Technology, a global transmission grid technology company focused on enabling the transition to renewable energy. Prior to this, she was the Senior Vice President, Global Finance for Wright Medical Group, a global medical device company focused on extremities and biologics that was acquired by Stryker in 2020. Ms. Andrews also held roles of increasing responsibility at Medtronic Inc. from 1998 to 2012, including serving as Vice President of Finance for the Spine and Biologics division where she oversaw all FP&A and accounting functions.

Orthofix Medical Inc. (NASDAQOFIX), a leading global spine and orthopedics company, today announced preliminary unaudited fourth quarter 2023 net sales of approximately $200.3 million, an increase of 63.8% on a reported basis and 62.8% on a constant currency basis versus fourth quarter 2022. For the full year 2023, preliminary unaudited net sales were approximately $746.5 million, an increase of 62.0% on a reported basis and 61.5% on a constant currency basis.

Orthofix Medical Inc. (NASDAQOFIX), a leading global spine and orthopedics company, today announced that effective immediately, Massimo Calafiore has assumed the role of President and Chief Executive Officer (CEO) and as a member of the Orthofix Board of Directors. In conjunction with Mr. Calafiore stepping into his role as CEO, the Company has announced the appointment of Julie Andrews as Chief Financial Officer. Ms. Andrews previously served as CFO for Smart Wires Technology, where she led all finance, tax, treasury, accounting, information technology, and investor relations functions. Prior to that role, Ms. Andrews served as the Senior Vice President, Global Finance for Wright Medical Group, a global medical device company focused on extremities and biologics that was acquired by Stryker in 2020, and before that, she was the Vice President of Finance for the Spine and Biologics division of Medtronic Inc.

Orthofix Medical Inc. (NASDAQOFIX), a leading global spine and orthopedics company, today announced the publication of new data from a prospective, multicenter study investigating Pulsed Electromagnetic Field (PEMF) stimulation as an adjunct therapy to lumbar spinal fusion procedures in patients at risk for pseudarthrosis. Published in the International Journal of Spine Surgery1, patients treated with the SpinalStim™ bone growth therapy device demonstrated a high rate of successful fusion with significant improvements in pain, function and quality of life, despite having risk factors for pseudarthrosis.

Orthofix Medical Inc. (NASDAQOFIX) (“Orthofix” or the “Company”) today announced the appointment of three new independent directors to the Company’s Board. These new directors bring substantial finance, strategic development, healthcare and medical technology experience to further advance Orthofix’s position as a leading global spine and orthopedics company. The appointments follow constructive engagement and entry into a cooperation agreement with Engine Capital Management, LP (together with its affiliates, “Engine”), one of the Company’s largest shareholders, which owns approximately 8.2% of Orthofix’s outstanding shares.

Orthofix Medical Inc. (NASDAQOFIX), a leading global spine and orthopedics company, today announced the publication of the five-year results from the U.S. clinical study comparing the M6-C™ artificial cervical disc with anterior cervical discectomy and fusion (ACDF). Published in The Spine Journal, patients treated with the M6-C disc demonstrated superior clinical success at 60 months compared to ACDF patients. Secondary findings indicated significant improvements in neck and arm pain, function, and quality of life scores. The M6-C patient group maintained the flexion-extension and lateral bending motion reported at earlier time points. The publication of this data coincides with the recognition that more than 100,000 implantations of the M6-C artificial cervical disc and the M6-L artificial lumbar disc (only available outside the U.S.) have been performed worldwide since the product’s first introduction in 2006.

Orthofix Medical Inc. (NASDAQOFIX), a leading global spine and orthopedics company, announced today that Massimo Calafiore has been named incoming President and Chief Executive Officer. Mr. Calafiore is currently Chief Executive Officer of LimaCorporate S.p.A., a global orthopedics company, and his appointment to Orthofix is expected to be effective in early 2024, following the completion of LimaCorporate’s previously announced acquisition by Enovis Corporation NYSE: ENOVNYSEENOV)

Orthofix Medical Inc. (NASDAQOFIX) today reported its financial results for the quarter ended September 30, 2023. Net sales were $184.0 million, earnings per share (“EPS”) was $(0.77), and adjusted EPS was $0.07.

Orthofix Medical Inc. (NASDAQOFIX), a leading global spine and orthopedics company, today announced the full U.S. commercial launch of the WaveForm® L Lateral Lumbar Interbody System. Designed for lateral lumbar interbody fusion (LLIF) procedures, the 3D-printed WaveForm L features a porous structure that prioritizes strength and stability to provide a robust fusion environment.

Orthofix Medical Inc. (NASDAQOFIX), a leading global spine and orthopedics company, today announced that it will release its third quarter 2023 financial results on Wednesday, November 8, 2023 after market close. The Company will host a conference call and webcast to review results at 4:30 p.m. ET the same day.

Orthofix Medical Inc. (NASDAQOFIX), a leading global spine and orthopedics company, today announced the 510k clearance and full commercial launch of OsteoCove™, an advanced bioactive synthetic graft. Available in both a putty and strip configuration, OsteoCove was carefully formulated to provide superior bone-forming capabilities with best-in-class handling characteristics for a wide range of spine and orthopedic procedural applications.

Orthofix Medical Inc. (NASDAQOFIX), a leading global spine and orthopedics company, today announced the full U.S. commercial launch and successful completion of the first cases with the Galaxy Fixation Gemini™ system. The latest in the Galaxy product line, this stable external fixation system is provided in several sterile procedure kit configurations as a quick off-the-shelf solution for treating fractures that result from trauma in the lower and upper limbs.

Orthofix Medical Inc. (NASDAQOFIX), a leading global spine and orthopedics company, today announced that Catherine Burzik, Chair of the Orthofix Board of Directors, has been appointed Interim Chief Executive Officer; Geoffrey Gillespie, Orthofix Vice President, Corporate Controller, has been appointed Interim Chief Financial Officer; and Puja Leekha, Orthofix Senior Vice President, Chief Ethics and Compliance Officer, has been appointed Interim Chief Legal Officer. The appointments are effective immediately and follow the unanimous decision by the Board’s independent directors to terminate for cause Keith Valentine, John Bostjancic and Patrick Keran from those respective roles. The Board also requested that Mr. Valentine resign from the Board. The Board will immediately begin a search for permanent successors.

Orthofix Medical Inc. (NASDAQOFIX), a leading global spine and orthopedics company, today announced that the Company will participate in the Morgan Stanley Healthcare Conference in New York City. Management is scheduled to present on Tuesday, September 13, 2023 at 1:35 p.m. ET.

Orthofix Medical Inc. (NASDAQOFIX), a leading global spine and orthopedics company, today announced the full commercial launch and successful completion of the first cases in the U.S. with the 7D FLASH™ Navigation System Percutaneous Module 2.0. The Percutaneous Module 2.0 provides new planning features and increased functionality for the 7D FLASH Navigation System, allowing Orthofix to further serve the Minimally Invasive Surgery (MIS) spine market, estimated at approximately $1.8 billion in the U.S.1

Orthofix Medical Inc. (NASDAQOFIX), a leading global spine and orthopedics company, today announced that the company will host an Investor Day at the Lewisville, TX headquarters on Wednesday, September 20, 2023 at 1:00pm Central Time.

Orthofix Medical Inc. (NASDAQOFIX) today reported its financial results for the quarter ended June 30, 2023. Net sales were $187.0 million, earnings per share (“EPS”) was $(1.07), and adjusted EPS was $0.02.

Orthofix Medical Inc. (NASDAQOFIX), a leading global spine and orthopedics company, today announced that it will release its second quarter 2023 financial results on Tuesday, August 8, 2023 after market close. The Company will host a conference call and webcast to review results at 4:30 p.m. ET the same day.

Orthofix Medical Inc. (NASDAQOFIX), a leading global spine and orthopedics company, today announced the launch of the TrueLok™ Phantom and Tornado Hinges, the latest addition to the Orthopedics TrueLok circular frame portfolio. Both hinges are designed for use with TrueLok circular frame offerings, including the TrueLok EVO Ring Fixation System introduced globally last year. The TrueLok EVO System is the only circular ring construct on the market that consists of both radiolucent rings and struts for clearer visualization of the bone under X-ray while also providing a lightweight frame for patient comfort.

Orthofix Medical Inc. (NASDAQOFIX), a leading global spine and orthopedics company, today announced that Catherine Burzik has been re-appointed as the Chair of the Company’s Board of Directors. Additionally, shareholders re-elected Wayne Burris who previously served on the Orthofix board from 2021-2022. Burris will serve on the Audit and Finance and Compliance and Ethics Committees. As previously announced Jon Serbousek, who served as Executive Chairman of the Board, did not stand for re-election at the annual shareholders meeting held yesterday.

Orthofix Medical Inc. (NASDAQOFIX), a leading global spine and orthopedics company, today announced the full commercial launch of the WaveForm® A interbody for Anterior Lumbar Interbody Fusion (ALIF) procedures. The WaveForm A interbody seamlessly integrates with the company’s Meridian ALIF system for treating patients in need of fusion due to degenerative disc disease. The proprietary wave-like design of the WaveForm A interbody provides a balance of strength, porosity and stability, with a large implant graft aperture for bone graft material to aid in creating an osteoinductive environment to optimize supplemental fixation procedures.

Orthofix Medical Inc. (NASDAQOFIX) today reported its financial results for the quarter ended March 31, 2023. Net sales were $175.2 million, earnings per share (“EPS”) was $(1.71), and adjusted EPS was $(0.10).

Orthofix Medical Inc. (NASDAQOFIX), a leading global spine and orthopedics company, today announced that the STIM onTrack™ mobile app was recognized as the “Best Patient Engagement Mobile App” by MedTech Breakthrough, an independent market intelligence organization that recognizes the top companies, technologies and products in the global health and medical technology market.

Orthofix Medical Inc. (NASDAQOFIX), a leading global spine and orthopedics company, today announced that it will release its first quarter 2023 financial results on Tuesday, May 9, 2023 after market close. The company will host a conference call and webcast to review results at 4:30 p.m. ET the same day.

Orthofix Medical Inc. (NASDAQOFIX), a leading global spine and orthopedics company, today announced the full commercial launch of two access retractor systems to aid surgeons during minimally invasive spine (MIS) procedures. The Lattus™ Lateral Access System and the Fathom™ Pedicle-Based Retractor System expand the Company’s offering of access solutions to address the estimated $1.8 billion MIS surgery market.

Orthofix Medical Inc. (NASDAQOFIX), a leading global spine and orthopedics company, today announced Fitbone™ TAA intramedullary limb-lengthening system has passed 5,000 devices implanted to date with more than 20 years of clinical history demonstrating safety and effectiveness in limb lengthening and deformity correction in adults and children.

(NASDAQOFIX) The merger of Orthofix Medical Inc. ("Orthofix") and SeaSpine Holdings Corporation ("SeaSpine") became effective as of January 5, 2023. This news release includes the financial results of stand-alone Orthofix and stand-alone SeaSpine for the fourth quarter and full year ended December 31, 2022. As such, these financial results do not include any potential accounting adjustments the merger may have on future net sales or operating results.

Orthofix Medical Inc. (NASDAQOFIX), a leading global spine and orthopedics company, today announced that it will host an Analyst Teach-In Meeting in Lewisville, TX on Monday, March 13, 2023 from 2:30 - approximately 6:30 p.m. CT.

Orthofix Medical Inc. (NASDAQOFIX), a leading global spine and orthopedics company, today announced that the Company will present at the upcoming Canaccord Genuity 2023 Musculoskeletal Conference in Las Vegas, NV. Management is scheduled to present on Tuesday, March 7, 2023, at 2:00 p.m. PT.

Orthofix Medical Inc. (NASDAQOFIX), a leading global spine and orthopedics company, today announced that it will release its fourth quarter 2022 financial results of stand-alone Orthofix as well as stand-alone SeaSpine, which was merged into Orthofix effective January 5, 2023, on Monday, March 6, 2023 after market close. The company will host a conference call and webcast to review results at 4:30 p.m. ET the same day.

Orthofix Medical Inc. (NASDAQOFIX), a leading global spine and orthopedics company, today announced the full commercial launch of, and first patient cases involving, the Mariner® Deformity Pedicle Screw System.

(NASDAQOFIX) The merger of equals between Orthofix Medical Inc. ("Orthofix") and SeaSpine Holdings Corporation ("SeaSpine") became effective as of January 5, 2023. This news release includes the pre-merger unaudited preliminary net sales results of stand-alone SeaSpine and stand-alone Orthofix for the fourth quarter and full year ended December 31, 2022. As such, these preliminary financial results do not include any potential accounting adjustments that the merger may have on future net sales results.

Orthofix Medical Inc. (NASDAQOFIX) and SeaSpine Holdings Corporation today announced the successful completion of their previously announced merger of equals following the approval of each company’s stockholders at respective special meetings of stockholders held today. Of votes cast, 99% of SeaSpine common shares were voted in approval of the merger, and 98% of Orthofix common shares were voted in approval of the merger.

Orthofix Medical Inc. (NASDAQOFIX), a global medical device company with a spine and orthopedics focus, today announced results from a prospective, multicenter clinical study evaluating the safety and efficacy of the Trinity Elite™ cellular bone allograft (CBA) in lumbar spinal fusion procedures. Published in Neurology International, patients treated with the Trinity Elite CBA demonstrated fusion rates of 98.6 percent, measured by bridging bone at 12 months follow-up.

Orthofix (NASDAQOFIX), a global medical device company with a spine and orthopedics focus, and SeaSpine NASDAQ: SPNENASDAQSPNE)

Orthofix Medical Inc. (NASDAQOFIX), a global medical device company with a spine and orthopedics focus, today announced that President and Chief Executive Officer Jon Serbousek and Chief Financial Officer Doug Rice will participate in a fireside chat during the upcoming Stifel 2022 Healthcare investor conference on Wednesday, November 16, 2022 at 8:00 a.m. ET. The conference will be held live at the Lotte New York Palace in NYC and one-on-one meetings will be held immediately following the fireside chat.

Orthofix Medical Inc. (NASDAQOFIX) today reported its financial results for the quarter ended September 30, 2022. Net sales were $114.0 million, earnings per share (“EPS”) was $(0.53), and adjusted EPS was $0.13.

Orthofix Medical Inc. (NASDAQOFIX), a global medical device company with a spine and orthopedics focus, today announced that it will release its third quarter 2022 financial results before market open on Thursday, November 3, 2022. Jon Serbousek, President and Chief Executive Officer, and Doug Rice, Chief Financial Officer, will host a conference call and webcast to review the Company’s results at 8:30 a.m. ET the same day.

Orthofix Medical Inc. (NASDAQOFIX), a global medical device company with a spine and orthopedics focus, today announced the full market release and first implants of Legacy Demineralized Bone Matrix (DBM), a putty for filling voids or gaps in boney defects or traumatic injuries of the spine, pelvis or extremities. Legacy DBM is processed by MTF Biologics, leveraging decades of experience through tailored processing methods that preserve the inherent growth factors natural to the bone.

Orthofix Medical Inc. (NASDAQOFIX), a global medical device company with a spine and orthopedics focus, today announced that the Virtuos™ Lyograft has received the 2022 Spine Technology Award from Orthopedics This Week, the most widely read publication in the Orthopedics industry. The Best Technology in Spine award will be presented today at the North American Spine Society (NASS) annual meeting in Chicago and published in upcoming issues of Orthopedics This Week and Orthopedics This Month Spine.

Orthofix Medical Inc. (NASDAQOFIX) today announced preliminary unaudited third quarter 2022 net sales of approximately $114 million, an increase of 1% on a reported basis and 5% on a constant currency basis versus the prior year. For the nine months ended September 30, 2022, preliminary unaudited net sales were approximately $339 million, which was flat to prior year on a reported basis and an increase of 2% on a constant currency basis.

Orthofix (NASDAQOFIX), a global medical device company with a spine and orthopedics focus, and SeaSpine NASDAQ: SPNENASDAQSPNE)

Orthofix Medical Inc. (NASDAQOFIX), a global medical device company with a spine and orthopedics focus, today announced the presentation of long-term evidence highlighting the clinical management of cervical disc arthroplasty during the North American Spine Society (NASS) 2022 annual meeting October 12-15 in Chicago.

Orthofix Medical Inc. (NASDAQOFIX), a global medical device company with a spine and orthopedics focus, today announced that President and Chief Executive Officer Jon Serbousek and Chief Financial Officer Doug Rice will be presenting during the upcoming Sidoti Virtual Investor Conference on Wednesday, September 21, 2022 at 10:00 a.m. ET. The conference will be held in a virtual format, and one-on-one meetings will also be held throughout the day.

Orthofix Medical Inc. (NASDAQOFIX) today reported its financial results for the quarter ended June 30, 2022. Net sales were $118.1 million, earnings per share (“EPS”) was $0.12, and adjusted EPS was $0.08.

Orthofix Medical Inc. (NASDAQOFIX), a global medical device company with a spine and orthopedics focus, today announced a strategic partnership agreement with CGBio, a developer of innovative, synthetic bone grafts currently used clinically in Asia for spine, orthopedic, trauma and dental applications. The two companies will work together for clinical development and commercialization of Novosis™ recombinant human bone morphogenetic protein-2 (rhBMP-2) bone growth materials and other future tissue regenerative solutions for the U.S. and Canadian markets.

Orthofix Medical Inc. (NASDAQOFIX), a global medical device company with a spine and orthopedics focus, today announced that it will release its second quarter 2022 financial results before market open on Friday, August 5, 2022. Jon Serbousek, President and Chief Executive Officer, and Doug Rice, Chief Financial Officer, will host a conference call and webcast to review the Company’s results at 8:30 a.m. ET the same day.

Orthofix Medical Inc. (NASDAQOFIX), a global medical device company with a spine and orthopedics focus, today announced the limited market release and first patient implant of the Virtuos™ Lyograft, a first-of-its-kind, shelf-stable and complete autograft substitute for spine and orthopedic procedures. This allograft is prepared by MTF Biologics through a proprietary process that preserves all biologic components necessary for bone healing within the graft. Virtuos is provided in a room-temperature, ready-to-use, moldable form.